{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-006558","form_type":"8-K","ticker":"BAX","cik":"0000010456","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.789295+00:00","generated_at":"2026-05-26T07:55:13.878187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Baxter Q4 adj EPS $0.58 beats guidance; Q4 sales $2.75B (+2% CC)","bullets":["Q4 sales from continuing ops $2.75B, up 1% reported / 2% constant currency, exceeding guidance.","GAAP diluted EPS loss ($0.95); adjusted EPS $0.58, ahead of company's guidance range.","Full-year 2024 sales $10.64B (+3% reported & CC); adjusted EPS $1.89, exceeded guidance.","Sale of Kidney Care business completed, streamlining Baxter for next stage of growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-006558","json":"https://secwatch.observer/filing/0001628280-25-006558.json","markdown":"https://secwatch.observer/filing/0001628280-25-006558.md","text":"https://secwatch.observer/filing/0001628280-25-006558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000162828025006558/0001628280-25-006558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000162828025006558/bax-20250220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T07:55:13.878187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}